

All of claims were rejected under 35 USC 112, second paragraph, as being indefinite in the expression "arterial thrombotic complications associated with atherosclerosis."

Applicant respectfully traverses this ground of rejection since the amended claims are believed to comply with 35 USC 112. Claim 8 has now been amended to be directed to a method of combatting the development of atherosclerosis and this is clearly supported by the last paragraph of page 6 of the application. Therefore, the claims are not indefinite and withdrawal of this ground of rejection is requested.

All of the claims stand rejected under 35 USC 103 as being anticipated by Agouridas et al which, according to the Examiner, teaches a method of combatting bacterial infection in warm-blooded animals by administering an effective amount of a ketolide or a salt thereof and therefore, the Examiner deems the claims to be directed to the same treatment as the reference.


Applicant respectfully traverses this ground of rejection since the Agouridas et al patent does not anticipate or render obvious Applicant's invention which is drawn to a method of combatting the development of atherosclerosis. The reference cited by the Examiner merely teaches that ketolides can combat bacterial infections. The prior art teaches that chlamydia pneumonia does not cause atherosclerosis but has been found as being useful as an

antibacterial agent to combat increase in the disease and this is not the same. Applicant will concede that ketolides are known to be active against microorganisms including chlamydia pneumonia and this is the subject of the Argouridas et al patent. However, it was not known that ketolides had any anti-platelet aggregating activity and Applicant has discovered that in addition to the antibacterial activity of the ketolides exhibit an interesting anti-platelet aggregating activity and use the advantage for the original treatment of atherosclerosis such as myocardial infraction, cerebrovascular accidents and unstable angina following atherosclerosis. One of the advantages of Applicant's treatment is that it permits a reduction in the number of drugs used in such a situation since it usually requires anti-thrombotics, anti-hypertensives, hypocholesterolemiants and antibiotics for the treatment. Therefore, it is deemed that the patent is no way anticipates or renders obvious Applicant's invention and withdrawal of this ground of rejection is requested.

In view of the amendments to the claims and the above remarks, it is believed that the claims clearly point out Applicant's patentable contribution and favorable reconsideration of the application is requested.

Respectfully submitted,  
Bierman, Muserlian and Lucas

By:

  
Charles A. Muserlian #19,683  
Attorney for Applicants  
Tel.# (212) 661-8000

CAM:ds



Marked up version  
of claims

RECEIVED

MAR 06 2002

Our Ref.: 146.1339

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :  
PCT/FR98/02436 : PCT Date: November 16, 1998  
Francis PETIT :  
Serial No.: :  
Filed: Concurrently Herewith :  
For: USE OF...ATHEROSCLEROSIS :  
600 Third Avenue  
New York, NY 10016

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Please amend this application as follows:

IN THE SPECIFICATION:

Page 1, before line 1, insert

--This application is a 371 of PCT/FR98/02436 filed  
November 16, 1998.--


IN THE CLAIMS:

Cancel claims 1, 2 and 7 and add the following claims.

--8. A method of ~~preventing~~ <sup>combating the development of</sup> arterial thrombotic complications ~~associated with~~ atherosclerosis in warm-blooded animals comprising administering to warm-blooded animals an effective amount of a

ketolide or its non-toxic, pharmaceutically acceptable acid addition salts sufficient to ~~prevent arterial thrombotic complications associated with atherosclerosis.~~ <sup>combat the development of</sup>

9. The method of claim 8 wherein the ketolide has the formula



I

wherein R is  $-(CH_2)_mO_n(X)YAr$ , m and n are individually 0 or 1, X is selected from the group consisting of  $-(NH_2)-$ ,  $-CH_2-$  and  $-SO_2-$ , a is 0 or 1, Y is  $-(CH_2)_b-(CH=CH)_c-(CH_2)_d-$ , c is 0 or 1,  $b + c + d \leq 8$ , Z is hydrogen or halogen and Ar is unsubstituted or substituted phenyl or heteroaryl.

Claim 3, cancel line 1 and insert --The method of claim 8 wherein the--.

Claims 4, 5 and 6, cancel line 1 of each and insert --The